Clinical Oncology
Volume 21, Issue 1 , Pages 43-48 , February 2009

New Prognostic Index to Predict Survival in Patients with Cancer of Unknown Primary Site with Unfavourable Prognosis

  • D. Trivanović

      Affiliations

    • Department of Oncology, General Hospital Pula, Croatia
    • Corresponding Author InformationAuthor for correspondence: D. Trivanović, Department of Internal Medicine, General Hospital Pula, Negri 6, 52100 Pula, Croatia. Tel: +385-523-76263, 376-173; Fax: +385-523-93901.
    • ,
  • M. Petkovic

      Affiliations

    • Department of Radiotherapy and Oncology, University Hospital Rijeka, Croatia
    • ,
  • D. Stimac

      Affiliations

    • Department of Gastroenterology, University Hospital Rijeka, Croatia

Received 12 June 2008 ,Revised 1 September 2008 ,Accepted 25 September 2008.

References 

  1. Greco FA, Hainsworth JD. Cancer of unknown primary site. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: principles and practice of oncology. 6th edn. Philadelphia: Lippincott Williams ands Wilkins; 2001;p. 2537–2560
  2. Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med. 1993;329:257–263
  3. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995;13:2094–2103
  4. Muir C. Cancer of unknown primary site. Cancer. 1995;75(Suppl. 1):353–356
  5. Van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in southeast Netherlands, 1984–1992. Eur J Cancer. 2002;38:409–413
  6. Mayordomo JI, Guerra JM, Guijarro C, et al. Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. Tumori. 1993;79:321–324
  7. Naresh KN. Do metastatic tumours from an unknown primary reflect angiogenic incompetence of the tumour at the primary site? — a hypothesis. Med Hypotheses. 2002;59:357–360
  8. Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Ordon˜ez NG, Abbruzzese JL. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?. J Clin Oncol. 1997;15:2056–2066
  9. Abbruzzese JL, Abbruzzese MC, Hess KR, et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994;12:1272–1280
  10. Van der Gaast A, Verweij J, Planting AS, Hop WC, Stoter G. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol. 1995;13:1720–1725
  11. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22:263–302
  12. Toivonen L. More light on QT interval measurement. Heart. 2002;87:193–194
  13. Goldberg RJ, Bengtson J, Chen ZY, et al. Duration of the QT interval and total and cardiovascular mortality in healthy persons (The Framingham Heart Study experience). Am J Cardiol. 1991;67:55–58
  14. Pavlidis N. Cancer of unknown primary: biological and clinical characteristics. Ann Oncol. 2003;14(Suppl 3):11–18
  15. Culine S, Kramar A, Saghatchian M, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002;20:4679–4683
  16. Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990–2005
  17. Van de Wouw AJ, Jansen RL, Griffioen AW, Hillen HF. Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res. 2004;24:297–301
  18. Pouessel D, Thezenas S, Culine S, et al. Hepatic metastases from carcinomas of unknown primary site. Gastroenterol Clin Biol. 2005;29:1224–1232
  19. Seve P, Ray-Coquard I, Trillet-Lenoir V, et al. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer. 2006;107:2698–2705
  20. Seve P, Sawyer M, Hanson J, et al. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. Cancer. 2006;106:2058–2066
  21. Suh SY, Ahn HY. Lactate dehydrogenase as a prognostic factor for survival time of terminally ill cancer patients: a preliminary study. Eur J Cancer. 2007;43:1051–1059
  22. Shaw PHS, Adams R, Jordan C, Crosby TDL. A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network. Clin Oncol. 2007;19:87–95
  23. Randen M, Lewin F, Helde Franklin M, Johansson H, Lagerros C, Rutqvist LE. Cancer with unknown primary — implementation of a regional referral process and clinical practice guidelines. Clin Oncol. 2008;20:564
  24. Seve P, Mackey J, Sawyer M. Impact of clinical practice guidelines on the diagnostic strategy for carcinomas of unknown primary site: a controlled ‘before – after’ study. Clin Oncol. 2008;20:658–659
  25. Shah RR. Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead. Drug Saf. 2005;28:1009–1028
  26. Curigliano G, Spitaleri G, Fingert HJ, et al. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur J Cancer. 2008;44:494–500
  27. Dekker JM, Schouten EG, Klootwijk P, et al. Association between QT interval and coronary heart disease in middle-aged and elderly men: the Zutphen study. Circulation. 1994;90:779–785
  28. De Bruyne MC, Hoes AW, Kors JA, et al. Prolonged QT interval predicts cardiac and all-cause mortality in the elderly. The Rotterdam Study. Eur Heart J. 1999;20:278–284
  29. Elming H, Holm E, Jun L, et al. The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. Eur Heart J. 1998;19:1391–1400
  30. Varterasian M, Meyer M, Fingert H, et al. Baseline heart rate-corrected QT and eligibility for clinical trials in oncology. J Clin Oncol. 2003;21:3378–3379
  31. Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res. 1999;5:3403–3410
  32. Trivanovic D, Petkovic M, Stimac D. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer. 2007;109:2623–2624
  33. Ponce Lorenzo J, Segura Huerta A, Díaz Beveridge R, et al. Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables. Clin Transl Oncol. 2007;9:452–458

PII: S0936-6555(08)00404-4

doi: 10.1016/j.clon.2008.09.007

Clinical Oncology
Volume 21, Issue 1 , Pages 43-48 , February 2009

Article Tools

* Image Usage & Resolution